ALNY vs. QGEN: Alnylam Pharmaceuticals vs. Qiagen Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Qiagen (QGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Qiagen (QGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while QGEN is classified in Life Sciences Tools & Services.
| Profile Item | ALNY | QGEN |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Qiagen N.V. |
| Country/Region | United States | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 20.89 billion USD | 10.39 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2004 | June 28, 1996 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | QGEN |
|---|---|---|
| Total Return (1Y) | -64.57% | 17.09% |
| Total Return (3Y, Annualized) | -1.58% | 10.44% |
| Total Return (5Y, Annualized) | -3.13% | -0.72% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | QGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 35.52% |
| Beta (5Y) | 0.45 | 0.56 |
| Max Drawdown (5Y) | -68.25% | -41.97% |
| Avg. Volume (3M) | 1.90M | 3.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | QGEN |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 0.36 |
| Sortino Ratio (1Y) | -1.45 | 0.60 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Qiagen (QGEN) at 10.81% also sits in the top quartile.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.81%
- Max
- 109.18%
- QGEN
- 10.81%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Qiagen (QGEN) at 18.20% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.20%
- QGEN
- 18.20%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Qiagen (QGEN) at 27.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.75%
- Max
- 83.12%
- QGEN
- 27.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | QGEN |
|---|---|---|
| ROE (TTM) | 138.07% | 10.81% |
| ROA (TTM) | 9.51% | 5.68% |
| Net Margin (TTM) | 52.85% | 18.20% |
| Operating Margin (TTM) | 23.72% | 27.75% |
| Gross Margin (TTM) | 77.28% | 67.06% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Qiagen (QGEN) at 5.65% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Only one side can be read here: Qiagen (QGEN) reports EPS growth of 409.76%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | QGEN |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 5.65% |
| Revenue Growth (3Y CAGR) | 52.98% | -0.81% |
| EPS Growth (YoY) | -- | 409.76% |
| EPS Growth (3Y CAGR) | -- | -0.19% |
Financial Strength
Current Ratio (MRQ)
Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Qiagen (QGEN) at 2.63 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- QGEN
- 2.63
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Qiagen (QGEN) at 0.47 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.47
- Max
- 1.42
- Q3
- 0.65
- QGEN
- 0.47
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | QGEN |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 2.63 |
| Debt / Equity (MRQ) | 0.83 | 0.47 |
| Net Debt / EBITDA | -0.57 | 1.08 |
Dividends
Dividend Yield (TTM)
Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71%
- QGEN
- 0.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a payout of 18.21%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.21%
- QGEN
- 18.21%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | QGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.71% |
| Dividend Payout Ratio (TTM) | 0.00% | 18.21% |
Valuation
P/E Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Qiagen (QGEN) at 27.21 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.21
- Max
- 85.34
- Q3
- 43.46
- QGEN
- 27.21
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Qiagen (QGEN) at 4.91 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.91
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- QGEN
- 4.91
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Qiagen (QGEN) at 2.99 are valued close to their industries’ norm against book — neither stands out from peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- QGEN
- 2.99
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | QGEN |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 27.21 |
| P/S Ratio (TTM) | 4.17 | 4.91 |
| P/B Ratio (MRQ) | 5.79 | 2.99 |
| Free Cash Flow Yield (TTM) | 1.57% | 3.62% |